BPG is committed to discovery and dissemination of knowledge
Case Report
Copyright: ©Author(s) 2026.
World J Diabetes. Jun 15, 2026; 17(6): 121606
Published online Jun 15, 2026. doi: 10.4239/wjd.121606
Table 1 Timeline of clinical events and interventions in 2025
Date (2025)
Clinical events and interventions
MayOnset of progressive fatigue and symptoms of anemia
JuneVisited hematology clinic; Hb: 66 g/L, Cr: 220 μmol/L. Initial bone marrow cytology showed 5% plasma cells
July 13Admitted to the Department of Endocrinology for suspected DN
Mid of JulyDiscovery of the three clinical mismatches (anemia-renal, protein-albumin gap, and lack of hypertension/edema)
Late of JulyPerformed follow-up bone marrow biopsy and serum free light chain testing
August 10Confirmed diagnosis of λ-type multiple myeloma (stage III, group B)
August 30Transferred to hematology; initiated bortezomib and dexamethasone chemotherapy
September 18Follow-up: Hb rose to 84 g/L, Cr decreased to 147.8 μmol/L. Discharged after remission
Table 2 Comparative analysis of typical diabetic nephropathy vs. manifestations in this patient
Feature
Typical DN
Manifestations in this patient
Clinical significance
Anemia severityProportional to CKD stage (Hb approximately 90-100 g/L at eGFR 15-20 mL/minute/1.73 m2)Severe anemia (Hb nadir 62 g/L)Disproportionate anemia suggests bone marrow involvement
Proteinuria compositionPrimarily albumin (high UACR)Non-albumin protein (low UACR 52 mg/gvs high 24 hours-TP 1.07 g)Indicates “overflow” light chains rather than glomerular leak
Blood pressureUsually hypertensive due to volume overloadNormotensive (110/60 mmHg)Points toward tubulointerstitial damage over glomerular damage
EdemaCommon (systemic/peripheral)AbsentInconsistent with volume overload typical of advanced DN
Renal declineChronic and gradual progressionRapidly progressive renal insufficiencyRed flag for NDRD


Write to the Help Desk